synthroid
viatris limited - levothyroxine sodium 300ug (plus a 9% manufacturing overage); levothyroxine sodium 300ug (plus a 2% manufacturing overage) - tablet - 300 mcg - active: levothyroxine sodium 300ug (plus a 9% manufacturing overage) excipient: acacia brilliant blue fcf lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose sunset yellow aluminium lake active: levothyroxine sodium 300ug (plus a 2% manufacturing overage) excipient: acacia brilliant blue fcf lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose sunset yellow aluminium lake - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.
synthroid
viatris limited - levothyroxine sodium 50ug (plus a 3% manufacturing overage); levothyroxine sodium 50ug (plus a 9% manufacturing overage) - tablet - 50 mcg - active: levothyroxine sodium 50ug (plus a 3% manufacturing overage) excipient: acacia lactose monohydrate magnesium stearate povidone purified talc sucrose active: levothyroxine sodium 50ug (plus a 9% manufacturing overage) excipient: acacia lactose monohydrate magnesium stearate povidone purified talc sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.
synthroid
viatris limited - levothyroxine sodium 75ug (plus a 3% manufacturing overage); levothyroxine sodium 75ug (plus a 9% manufacturing overage) - tablet - 75 mcg - active: levothyroxine sodium 75ug (plus a 3% manufacturing overage) excipient: acacia allura red ac indigo carmine lactose monohydrate magnesium stearate povidone purified talc sucrose active: levothyroxine sodium 75ug (plus a 9% manufacturing overage) excipient: acacia allura red ac indigo carmine lactose monohydrate magnesium stearate povidone purified talc sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.
synthroid
viatris limited - levothyroxine sodium 88ug (plus a 3% manufacturing overage); levothyroxine sodium 88ug (plus a 9% manufacturing overage) - tablet - 88 mcg - active: levothyroxine sodium 88ug (plus a 3% manufacturing overage) excipient: acacia d&c olive lake blend lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose active: levothyroxine sodium 88ug (plus a 9% manufacturing overage) excipient: acacia d&c olive lake blend lactose monohydrate magnesium stearate povidone purified talc quinoline yellow sucrose - synthroid (levothyroxine sodium, usp) is indicated as replacement or supplemental therapy in patients of any age or state (including pregnancy) with hypothyroidism of any etiology except transient hypothyroidism during the recovery phase of subacute thyroiditis; specific indication include: primary hypothyroidism resulting from thyroid dysfunction, primary atrophy, or partial or total absence of thyroid gland, or from the effects of surgery, radiation or drugs, with or without the presence of goiter, including subclinical hypothyroidism; secondary (pituitary) hypothyroidism; and tertiary (hypothalamic) hypothyroidism.
edurant
j-c health care ltd - rilpivirine as hydrochloride - tablets - rilpivirine as hydrochloride 25 mg - rilpivirine - rilpivirine - edurant™, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in antiretroviral treatment-naïve adult patients with hiv-1 rna less than or equal to 100,000 copies/ml at the start of therapy.
victoza® solution for injection in pre-filled pen 6mgml
novo nordisk pharma (singapore) pte ltd - liraglutide - injection, solution - 6mg/ml - liraglutide 6mg/ml
stelara solution for injection 45mg0.5 ml
johnson & johnson international (singapore) pte ltd - ustekinumab - injection, solution - 45mg/vial - ustekinumab 45mg/vial
stelara™ solution for injection 90mg1ml
johnson & johnson pte. ltd. - ustekinumab - injection, solution - 90mg/vial - ustekinumab 90mg/vial
invokana™ film-coated tablets 100 mg
johnson & johnson international (singapore) pte ltd - canagliflozin hemihydrate 102mg eqv canagliflozin - tablet, film coated - 100 mg - canagliflozin hemihydrate 102mg eqv canagliflozin 100 mg
invokana™ film-coated tablets 300 mg
johnson & johnson international (singapore) pte ltd - canagliflozin hemihydrate 306mg eqv canagliflozin - tablet, film coated - 300 mg - canagliflozin hemihydrate 306mg eqv canagliflozin 300 mg